What are the side effects of Venlafaxine (Selective Norepinephrine Reuptake Inhibitor - SNRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Venlafaxine Side Effects

Venlafaxine has numerous significant side effects including dose-dependent blood pressure elevation, serious discontinuation syndrome, and increased risk of serious adverse events compared to other antidepressants, requiring careful monitoring and slow tapering when discontinuing. 1, 2, 3

Common Side Effects

  • Gastrointestinal effects are frequently reported, with nausea being the most common reason for discontinuation in clinical trials, along with vomiting, diarrhea, constipation, abdominal discomfort, and dry mouth 1
  • Neurological effects include dizziness, headache, tremor, insomnia, somnolence, and nervousness 1, 2
  • Autonomic effects, particularly diaphoresis (excessive sweating), occur more frequently with venlafaxine than with many other antidepressants 1, 2
  • Sexual dysfunction, including abnormal ejaculation/orgasm in men and sexual dysfunction in both women and men 1, 4
  • Decreased appetite and weight loss can occur during treatment, with 6% of patients experiencing a loss of 5% or more of body weight 1, 2

Cardiovascular Side Effects

  • Dose-dependent increases in blood pressure, with higher risk at doses above 300 mg/day 1, 5
  • Sustained clinical hypertension requiring monitoring, especially at higher doses 1, 6
  • Both systolic and diastolic blood pressure elevations have been reported 2, 5
  • Regular monitoring of blood pressure and pulse is recommended, especially when initiating treatment or adjusting dosage 6, 2

Serious Adverse Effects

  • Increased risk of suicidal thoughts and behavior, particularly in children, adolescents, and young adults up to age 24 years 2, 1
  • Serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, coma, coordination problems, racing heartbeat, fluctuating blood pressure, fever, nausea, vomiting, diarrhea, and muscle rigidity 2, 1
  • Discontinuation syndrome, characterized by withdrawal symptoms when stopping venlafaxine abruptly, requiring slow tapering when discontinuing 1, 7
  • Withdrawal symptoms include anxiety, irritability, sleep disturbances, headache, dizziness, electric shock-like sensations, tremor, and nausea, which can begin within hours of missed doses 2, 7
  • Seizures, though uncommon, may be triggered by venlafaxine 1, 2
  • Low sodium levels in the blood (hyponatremia), particularly in elderly patients 2

Special Populations and Considerations

  • Overdose risk is higher with venlafaxine compared to SSRIs, with more frequent fatal outcomes 8, 1
  • Concomitant use with MAOIs is contraindicated due to risk of serotonin syndrome 1, 2
  • Pediatric patients may experience weight loss and reduced growth during treatment 2
  • Pregnant women exposed to venlafaxine during the second and third trimesters have increased risk of pre-eclampsia and eclampsia 8
  • QT interval prolongation has been reported, which can lead to torsades de pointes, a potentially fatal type of ventricular tachycardia 8

Monitoring Recommendations

  • Regular monitoring of blood pressure and pulse is essential, especially when initiating treatment or adjusting dosage 6, 1
  • Screening electrocardiogram for patients older than 40 years with cardiac risk factors 6
  • Monitor weight regularly, particularly in pediatric patients 2
  • Careful observation for signs of suicidal thinking or behavior, especially early in treatment or with dose changes 2

Discontinuation Considerations

  • A slow, gradual discontinuation taper is essential to minimize withdrawal symptoms 1, 2
  • Abrupt discontinuation can lead to severe withdrawal symptoms affecting motor and coordination skills to such a degree that patients should be warned not to drive 7
  • If intolerable symptoms occur following a decrease in dose, resuming the previously prescribed dose may be considered before attempting a more gradual taper 2

References

Guideline

Side Effects of Venlafaxine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Venlafaxine:a novel antidepressant compound.

Expert opinion on investigational drugs, 1997

Guideline

Venlafaxine Side Effects and Monitoring

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Venlafaxine and serious withdrawal symptoms: warning to drivers.

MedGenMed : Medscape general medicine, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.